STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

Cassava Sciences (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer's disease, has announced it will hold a conference call and webcast on Thursday, November 7th, 2024, at 8:30 a.m. Eastern Time to report its third quarter 2024 results. The audio webcast will be accessible through the company's website and will remain available for replay for 90 days following the event.

Loading...
Loading translation...

Positive

  • None.

Negative

  • None.

News Market Reaction 1 Alert

-0.75% News Effect

On the day this news was published, SAVA declined 0.75%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Conference call and webcast to begin at 8:30 AM ET

AUSTIN, Texas, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, announced today that it will hold a conference call on Thursday, November 7th at 8:30 a.m. Eastern Time.

  
Event details:
  
Date:Thursday, November 7th
Time:8:30 a.m. Eastern Time
Audio Webcast:https://www.CassavaSciences.com/company-presentations
Or
Audio Webcast:https://edge.media-server.com/mmc/p/tzb9j3sy
  

A replay of the audio webcast will also be available on the “Company Presentations” page of the Cassava Sciences website for 90 days following the webcast.

About Cassava Sciences, Inc.
Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease.

Simufilam is Cassava Sciences’ small molecule oral drug candidate currently in Phase 3 clinical trials for the treatment of Alzheimer's disease. Simufilam targets a specific site on filamin A, a scaffolding protein that is critical to certain receptor interactions in the brain. Cassava Sciences believes that simufilam interrupts amyloid-β42 binding to receptors in the brain and may affect the Alzheimer's disease process. Cassava Sciences owns exclusive, worldwide rights to its investigational product candidates and related technologies, without royalty obligations to any third party.

For more information, please visit: https://www.CassavaSciences.com

For More Information Contact:

Investors
Sandya van der Weid
svonderweid@lifesciadvisors.com

Media
Sitrick And Company
Mike_Sitrick@Sitrick.com

Company
Eric Schoen, Chief Financial Officer
(512) 501-2450
ESchoen@CassavaSciences.com


FAQ

When will Cassava Sciences (SAVA) report Q3 2024 earnings?

Cassava Sciences will report its third quarter 2024 results on Thursday, November 7th, 2024, at 8:30 a.m. Eastern Time.

How can I access Cassava Sciences (SAVA) Q3 2024 earnings call?

The earnings call can be accessed via audio webcast through Cassava Sciences' website under 'Company Presentations' or directly through the provided media server link.

How long will Cassava Sciences (SAVA) Q3 2024 earnings call replay be available?

The audio webcast replay will be available on the 'Company Presentations' page of Cassava Sciences' website for 90 days following the webcast.
Cassava Sciences

NASDAQ:SAVA

SAVA Rankings

SAVA Latest News

SAVA Latest SEC Filings

SAVA Stock Data

152.17M
42.11M
12.79%
25.22%
12.69%
Biotechnology
Pharmaceutical Preparations
Link
United States
AUSTIN